financetom
Business
financetom
/
Business
/
Apple's iPhone sales capture top spot in Chinese market in May, Counterpoint Research says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Apple's iPhone sales capture top spot in Chinese market in May, Counterpoint Research says
Jun 12, 2025 11:38 PM

June 13 (Reuters) - Apple's ( AAPL ) iPhone sales rose

to the top spot in China in May, with global sales growing 15%

year-on-year during April and May in the tech giant's strongest

performance for the two-month period since the COVID-19

pandemic, data from Counterpoint Research showed.

The increase in global sales was primarily driven by a

return to growth in Apple's ( AAPL ) two largest markets, China and the

United States, preliminary data from Counterpoint Research

showed.

The company was aided in part by tariff dodgers and also saw

double-digit increases in Japan, India and the Middle Eastern

markets, Counterpoint said.

"Q2 iPhone performance looks promising at the moment, but as

always, swings either way are dictated by two markets - the U.S.

and China," Ivan Lam, Senior Analyst at Counterpoint Research

said.

Calculations based on data from the government-affiliated

China Academy of Information and Communications Technology

showed that April shipments of foreign-branded phones in China

rose to 3.52 million units from 3.50 million a year earlier.

Apple ( AAPL ) has faced increased competition from domestic rivals

in China and has resorted to price cuts to stay competitive.

Chinese e-commerce platforms were offering discounts of up

to 2,530 yuan ($351) on Apple's ( AAPL ) latest iPhone 16 models in May.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Core & Main's Fiscal Q3 Earnings, Net Sales Rise; Fiscal 2024 Sales Guidance Lifted
Core & Main's Fiscal Q3 Earnings, Net Sales Rise; Fiscal 2024 Sales Guidance Lifted
Dec 3, 2024
07:45 AM EST, 12/03/2024 (MT Newswires) -- Core & Main ( CNM ) reported fiscal Q3 earnings Tuesday of $0.69 per share, up from $0.65 a year earlier. Four analysts polled by FactSet expected $0.64. Net sales for the quarter ended Oct. 27 were $2.04 billion, up from $1.83 billion a year earlier. Analysts surveyed by FactSet expected $1.99 billion....
Top Premarket Decliners
Top Premarket Decliners
Dec 3, 2024
07:46 AM EST, 12/03/2024 (MT Newswires) -- TruBridge ( TBRG ) shares were down 22% pre-bell Tuesday following a muted session. KalVista Pharmaceuticals ( KALV ) stock was 22% lower after a 2.1% gain on Monday. Gelteq Ltd. ( GELS ) shares were down 21%, paring Monday's rally. Centuri Holdings ( CTRI ) stock was 21% lower after a 2.3%...
Dynamite Blockchain to Buy Kaspa Mining Limited For About C$4.8 Million
Dynamite Blockchain to Buy Kaspa Mining Limited For About C$4.8 Million
Dec 3, 2024
07:49 AM EST, 12/03/2024 (MT Newswires) -- Dynamite Blockchain (BLOX.CN) on Tuesday entered into a binding arm's length securities exchange agreement as it moved to buy all outstanding shares of Kaspa Mining Limited for a total consideration of about C$4.8 million. The total consideration for the acquisition will be 30 million common shares of the company, at a deemed issue...
Coherus BioSciences to Divest Udenyca to Intas Pharmaceuticals for Up to $558 Million
Coherus BioSciences to Divest Udenyca to Intas Pharmaceuticals for Up to $558 Million
Dec 3, 2024
07:47 AM EST, 12/03/2024 (MT Newswires) -- Coherus BioSciences ( CHRS ) said Tuesday that it has agreed to divest its biosimilar drug Udenyca, which is based on Amgen's ( AMGN ) Neulasta, to Intas Pharmaceuticals for up to $558.4 million. The company said the transaction includes an upfront payment of $483.4 million, as well as $75 million in potential...
Copyright 2023-2026 - www.financetom.com All Rights Reserved